Accelerated rTMS: Complexities and clinical translation

Major depressive disorder (MDD) is a severe and commonly occurring psychiatric illness with a substantial proportion of patients failing to respond adequately to standard treatments, often referred to as treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) has been developed as a safe and clinically effective intervention for TRD and is now increasingly accessible in routine clinical settings [1]. Although rTMS produces meaningful antidepressant effects for many patients, the standard delivery schedule is time intensive and clinical response typically occurs gradually.